Country/Region: China Mainland
Published PE Recommendations

China Guidelines for Pharmacoeconomic Evaluations (2020)
PDF in English

Published PE Recommendations Source:
Additional Information:
Information up to date as of Thursday, April 22, 2021

Published PE Recommendations Key Features:

Key Features:  
Title and year of the document
China Guidelines for Pharmacoeconomic Evaluations (2020) 
Affiliation of authors
Peking University, Fudan University, Tianjin University, China Pharmaceutical University, Ministry of Human Resources and Social Security (MHRSS), PLA 306 Hospital, and many others 
Purpose of the document
Provide scientific basis for researchers to conduct economic analysis of medicines for pricing and reimbursement policy making in China 
Standard reporting format included
Yes 
Disclosure
Yes 
Target audience of funding/ author's interests
Both public and private payers, healthcare industries, clinicians, and research communities 
Perspective
Primarily society and healthcare systems, followed by payers, health care provider, patients 
Indication
Primarily approved indications 
Target population
Both insured and uninsured populations, defined by inclusion and exclusion criteria 
Subgroup analysis
Yes 
Choice of comparator
Primarily standard care or conventional treatment 
Time horizon
Long enough to capture the major costs and outcomes related to the interventions. 
Assumptions required
Yes 
Preferred analytical technique
Primarily CUA 
Costs to be included
Primarily direct medical costs, followed by direct non-medical cost and indirect cost if data available 
Source of costs
Best available, including data from National Healthcare Security Administation (NHSA), and National Health Commission (NHC)  
Modeling
Yes, both decision-tree and econometric frameworks 
Systematic review of evidences
Yes 
Preference for effectiveness over efficacy
Efficacy should be based on the best available evidence (i.e., the best evidence among the clinical efficacy studies and effectiveness studies). For new drugs, if available and applicable, clinical efficacy data from a randomized controlled trial (RCT) is preferred; for drugs which have been in the market for years, when it is not possible to obtain new efficacy data or data is not applicable, effectiveness data from a real-world study should be used.  
Preferred outcome measure
Final Endpoints; QALY; WTP 
Preferred method to derive utility
EQ-5D (EuroQol-5 Dimensions), SF-6D (Short-Form Six-Dimensions), are recommended 
Equity issues stated
Yes 
Discounting costs
Base case: 5%; sensitivity analysis: 0-8% 
Discounting outcomes
Base case: 5%; sensitivity analysis: 0-8% 
Sensitivity analysis-parameters and range
All assumptions should be subject to sensitivity analysis. 
Sensitivity analysis-methods
One-way, multi-way, threshold analysis, analysis of extremes, scenario analysis, Monte Carlo simulation 
Presenting results
Reports both in disaggregated and aggregated form. 
Incremental analysis
Yes 
Total costs vs effectiveness (cost/effectiveness ratio)
Yes 
Portability of results (Generalizability)
Yes, PE study should address the extent to which both the input data and the results can be applied from one setting to another, both domestically and internationally if cross-country data is involved   
Financial impact analysis
Yes, budget impact analysis is recommended when data is available   
Mandatory or recommended or voluntary
Voluntary for now to start, expecting to be recommended in a few years 

Acknowledgement: Chinese Pharmaceutical Association, China Society for Pharmacoeconmics and Outcomes Research and ISPOR Beijing Chapter highly contributed to the Guidelines development and the key feature form.

Country Selection Page | PE Guidelines Index Page